Register for free to
view the full innovation profile.
This technology is a much safer, cutting-edge vaccine for canine distemper virus (CDV) that overcomes the potential pathogenicity found in current live CDV vaccines.
About
This technology
is a much safer, cutting-edge vaccine for canine distemper virus (CDV) that
overcomes the potential pathogenicity found in current live CDV vaccines. CDV
is a very contagious virus that can cause severe disease in young dogs and is
found worldwide. Unfortunately, the mortality rate of canine distemper
is about 50% in dogs and 80% in puppies.
While traditional
CDV vaccines rely on live attenuated pathogens, our approach creates a vaccine
that offers the same protective benefits with enhanced safety, by reducing the
risk of vaccine reversion to virulent viral form. This innovation makes our
vaccine a much safer choice for dogs of all ages and much more appealing
to dog owners.
This unique
CDV vaccine platform offers genetic stability, tunable strain attenuation, and
antigen flexibility. Those features ensure consistent effectiveness over time but
also allow adaptability for emerging strains. This vaccine platform could also potentially
prevent virulence from paramyxoviruses of different strains.
Key Benefits
- Much Safer: 100% of immunized animals survived infection with minimal symptoms. Peak viremia titers were slightly reduced compared to the unmodified parental strain.
- Tunable Vaccine Platform: through targeted adjustments, researchers can enhance the vaccine’s ability to stimulate a robust immune response while minimizing side effects
- Reduces Virus Replication: by targeting the replication of the canine distemper virus, this vaccine effectively mitigates the spread and severity of the disease among dogs.
- Versatile Application: this vaccine can target other pathogens from paramyxoviruses of different strains
Applications
·
Canine distemper
virus
prevention